Scientific Online Resource System

International Bulletin of Otorhinolaryngology

Risk Adapted Strategies in the Management of Thyroid Cancer

Jatin P. Shah, Cristina Valero Mayor

Abstract

There is a rising incidence of thyroid cancer world wide in the past four decades. Such a rise is observed most often in patients between the ages of 50-65. However, a majority of these newly discovered cancers are small, less than 2 cm in size, intrathyroidal papillary carcinomas. Understanding the tumor progression model of follicular cell derived cancers and appreciating the impact of prognostic factors allows the development of risk group stratification
at initial diagnosis and after surgical treatment. Employing risk group stratification permits discretion in selection of surgical treatment, in the use of adjuvant therapies, and the subsequent follow up strategies. Molecular analysis of aggressive cancers opens a path to the use of targeted therapies in patients with iodine resistant recurrent or metastatic thyroid cancers. A great majority of thyroid cancer patients fall into the low and intermediate risk groups, and their long-term outcomes remain excellent. Therefore, in conclusion, understanding the biology of thyroid cancer and appreciation of prognostic factors and employing risk group stratification is crucial for cost effective treatment of cancer of the thyroid gland.

Full Text


References

Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338-1348.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.

Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016 Aug 18;375(7):614-7.

Maniakas A, Davies L, Zafereo ME. Thyroid Disease Around the World. Otolaryngol Clin North Am. 2018 Jun;51(3):631-642.

Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22.

Amin MB, Edge SB, Greene F, et al (eds). American Joint Committee on Cancer. AJCC Cancer Staging Manual, Eighth Edition. Geneva, Switzerland: Springer; 2017.

American Thyroid Association. About the ATA. Available at: https://www.thyroid.org/about-american-thyroid-association (accessed October 4, 2019).

Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987 Dec;102(6):1088-95.

Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988 Dec;104(6):947-53.

Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8.

Ghaznavi SA, Ganly I, Shaha AR, English C, Wills J, Tuttle RM. Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. Thyroid. 2018 Oct;28(10):1293-1300.

Harries V, Wang LY, McGill M, et al. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? Surgery. 2019 Sep 9. pii: S0039-6060(19)30512-4.

Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014 Oct;260(4):601-5; discussion 605-7.

Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer. Surgery. 2016 Sep;160(3):738-46.

Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009 May;19(5):451-7.

Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 Oct 1;117(19):4439-46.

Marti JL, Jain KS, Morris LG. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid. 2015 Jun;25(6):681-7.

Khang AR, Cho SW, Choi HS, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2015 Jul;83(1):117-23.

Crispo F, Notarangelo T, Pietrafesa M et al. BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. Cancers (Basel). 2019 Sep 18;11(9). pii: E1388.




DOI: http://dx.doi.org/10.14748/orl.v16i2.6737

Refbacks

Font Size


|